Moderna reviews clinical trial programs across portfolio at 2022 r&d day

Interim data from phase 1/2 propionic acidemia (pa) multi-dose paramount trial shows mrna-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit interim data from phase 1/2 glycogen storage disease 1a (gsd1a) single-dose ba1ance trial shows mrna-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit moderna announces a new development candidate, mrna-3139, for ornithine transcarbamylase (otc) deficiency, a rare genetic disorder phase 3 clinical trial of rsv vaccine, mrna-1345, has enrolled more than 24,000 of the 34,000-participant target phase 3 immunogenicity and safety study of flu vaccine, mrna-1010, is fully enrolled; company to pursue accelerated approval pathway in 2023 company is on track to report data from its phase 2 personalized cancer vaccine (pcv) study in 4q 2022 cambridge, ma / accesswire / september 8, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced advances across its portfolio of mrna programs presented at the company's annual r&d day. "we continue to make significant progress in accelerating our pipeline.
MRNA Ratings Summary
MRNA Quant Ranking